Psoriasis Drug Will Undergo Further Research Trials To Test Effectiveness
After completing a proof-of-concept (PoC) clinical trial, Vitae Pharmaceutical’s psoriasis drug proved to show its efficacy worth through the reduction of psoriasis severity. As a result, it will be designated the opportunity to undergo further clinical research trials.
About The Psoriasis Drug
The drug itself is referred to as VTP-43742. Unlike most psoriasis drugs in the market, VTP-43742 finds itself as an oral therapy in an otherwise injectable treatment-market, with Novartis’ Cosentyx leading the pack.
Jeff Hatfield, Vitae Pharmaceutical’s CEO, said “we believe VTP-43742 has the potential to expand utilization of oral therapy in a variety of autoimmune disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease with an effective, safe and well tolerated, once-a-day agent.”
The current treatments for psoriasis inflammation come in the form of injections. Novartis’ Cosentyx blocks the activity of interleukin017 (IL-17), an inflammatory protein, which clears up psoriasis and psoriatic arthritis. VTP-43742 goes straight to the protein RORyt that secretes IL-17 and prevents it from carrying out such activity. In addition to this preventative measure, the company believes that the oral tablet will prove to be a highly marketable and effective alternative to injections.
The Clinical Research Trial Findings
While the 4 week initial trial did not show strong evidence of a statistical significance over the placebo, the company highlighted the fact that psoriasis therapies average around a 12-weeks of treatment in order to come about with hard evidence. In the meantime, Vitae Pharmaceuticals asserts the drug’s worth that the 4 week concept trial gives cause for a fully executed longer clinical trial. A 16 week study will begin during the second half of 2016.
The trial’s safety results showed no abnormalities – there were no serious side effects and the enzyme elevation changes in four patients were reversible. The oral drug was tolerated at 350 mg and 700 mg a day without any related cardiac abnormalities. Although a third higher dosage was planned, the minimal enzyme spikes gave cause for Vitae to decide against it.
The Next Steps: Patient Recruitment
So while Vitae Pharmaceutical’s Psoriasis drug managed to pass the PoC stage, this is just one of the very first steps in approving this new treatment. The PoC stage helps in linking between Phase-I and Phase-II dose ranging clinical research trials. What is needed from here is a larger sample of data, and therefore a larger number of patients willing to undergo such a study. If you or anyone you know is interested in learning more about registering for a clinical research trial like this one, sign up to be a patient with Clinical Trial Spotlight. Our vast pool of resources helps connect patients to clinical research trials all around the country. Together, we can advance the cause and fight these terrible diseases and conditions. Contact us if you have any further questions about clinical trials or signing up. Let’s end these plights together!